GPRC5D and Miyoshi myopathy: GPRC5D has recently gained significant attention in the field of cancer immunotherapy, particularly as a potential therapeutic target for hematologic malignancies such as MM.[10,39, 40, 41] In this study, we developed an integrative virtual screening workflow to identify potential small‐molecule inhibitors targeting GPRC5D, a promising therapeutic target for MM.